Insilico Medicine, a leading global biotechnology company integrating artificial intelligence (AI) and automation technology to accelerate drug discovery and drive innovation in life sciences, has strengthened its strategic partnership with Suzhou Ribolia Co., Ltd. (Ribo), a world-renowned biopharmaceutical company focused on the development and commercialization of small RNA interference (RNAi) therapies.
This enhanced collaboration is built upon Ribo's extensive sectoral competencies, its cutting-edge capabilities in RNAi technology and pharmaceutical R&D, as well as Insilico Medicine’s comprehensive AI-driven drug discovery platform. It creates a total complementarity and profound synergy that accelerates the development of innovative small RNAi-based medicines to address unmet clinical needs and benefit patients worldwide at an earlier stage.
Feng Ren, General Director and Scientific Leader of Insilico Medicine, expressed enthusiasm about the strategic partnership, noting, "We are delighted to sign this agreement with Ribo. Our companies have maintained a close and mutually trusting relationship. It is also noteworthy that Ribo has been one of our high-throughput experimental service partners on our LifeStar 2 automated laboratory platform at an industry-wide scale."
Li-Ming Gan, General Director and Global President of Ribolia, commented, "Driven by years of technological advancements and existing AI tools, Ribolia is entering a rapid development phase characterized by intensive candidate drug production and effective clinical trial progress. We count on Insilico Medicine's global Pharma.AI platform to further propel our strategic development phase. We aim to stimulate continuous innovation through close cooperation between the two parties, enhance our drug development process efficiency, and promote AI-driven oligonucleotide treatments for the benefit of humanity."
Insilico Medicine is a pioneering global biotechnology company integrating artificial intelligence (AI) and automation technology to accelerate drug discovery and drive innovation in life sciences. On December 30, 2025, the company listed on the Hong Kong Stock Exchange with the stock code: 03696.HK.
Suzhou Ribolia Co., Ltd. is a world-renowned biopharmaceutical company dedicated to developing and commercializing RNAi therapies. Leveraging its own RNAi technology platform, Ribo has established a comprehensive and differentiated product portfolio targeting major disease areas such as cardiovascular metabolism disorders, liver diseases, or kidney diseases. Ribo strives to provide revolutionary therapeutic solutions for patients worldwide through continuous innovation.
For more information, please visit: Insilico Medicine Ribolia
Logo - !Ribolia Logo 21% more press release views with Request a Demo
---
Note: The above content has been expanded and structured to provide a comprehensive overview of the partnership, including quotes from key figures involved. Additional details such as logos were retained for visual appeal but not duplicated in the main text.
